Skip to main content
logo
Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
102.90
+2.95 (2.95%)
Jul 30, 2025, 9:45 AM HKT

Innovent Biologics Revenue

In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.

Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
17.04
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
170.86B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20249.42B3.22B51.82%
Dec 31, 20236.21B1.65B36.21%
Dec 31, 20224.56B286.65M6.71%
Dec 31, 20214.27B425.91M11.08%
Dec 31, 20203.84B2.80B266.94%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
BeOne Medicines32.49B
Hansoh Pharmaceutical Group Company13.05B
JD Health International61.89B
Akeso2.26B
WuXi Biologics19.87B
Sino Biopharmaceutical30.72B
CSPC Pharmaceutical Group28.99B
Sichuan Kelun-Biotech Biopharmaceutical2.06B
Revenue Rankings

Innovent Biologics News

More News